Mon, Dec 22, 2014, 12:15 AM EST - U.S. Markets open in 9 hrs 15 mins


% | $
Quotes you view appear here for quick access.

Ironwood Pharmaceuticals, Inc. Message Board

  • extractofhuman extractofhuman Aug 31, 2012 10:05 AM Flag

    Cantor predicted this

    Sorry baggers, this isn't shorts,this was an overvalued company. Don't believe me,read what Cantor Fitzgerald said BEFORE approval: Cantor Fitzgerald reiterates a 'Sell' on Ironwood Pharmaceuticals (NASDAQ: IRWD) price target of $8.00.

    Analyst, Irina Rivkind, said, "We reiterate our SELL rating going into the Linaclotide PDUFA: We remain cautiously optimistic about a first pass approval (we estimate 70% probability) but maintain that the stock is overvalued and could sell off even under a best-case scenario (since investors may play the event and then exit the stock post-approval due to lack of pending positive catalysts). On the flip side, we think that a CRL would be catastrophic to the stock (drop of 30% or more). Under this second scenario, the company would continue to burn significant cash while it awaited FDA approval (which may expedite another financing round with the stock potentially trading at lower levels). We are also not expecting a near-term company takeout."

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
14.79-0.27(-1.79%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.